Ono Pharmaceutical Co., Ltd.

Ono Pharmaceuticalco.,ltd.

Kazuhiro Otsuki

Hiroshi Yamamoto

Atsushi Naganawa

Kensuke Kusumi

Tetsuya Sekiguchi

Koji Shinozaki

Akito Kakuuchi

Shigeyuki Nonaka

Yasuko Yamamoto

The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1Pantagonistic activity. The compound may therefore be used as a therapeutic agent for S1P-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

Phenyl derivative

An object of the present invention is to provide a compound having strong human S1Pantagonistic activity in order to develop a useful medicament for therapy of a S1P-mediated disease such as a disease resulting from vascular constriction, fibrosis and respiratory disease. The compound represented by the general formula (I), wherein all the symbols have the same meanings as described in the specification, has a halogen atom or a haloalkyl group and a phenoxy group at certain substitution sites, and thus has strong human S1Pantagonistic activity. Therefore, the compound can be a therapeutic agent for a S1P-mediated disease, such as a disease resulting from vascular constriction, fibrosis and respiratory disease. 

The compound represented by the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1Pantagonistic activity. The compound may therefore be used as a therapeutic agent for S1P-mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.

Growing community of inventors

Osaka, Japan

Kazuhiro Otsuki